Journal Mobile Options
Table of Contents
Vol. 215, No. 2, 2007
Issue release date: August 2007
Dermatology 2007;215:164–165
(DOI:10.1159/000104271)
Letters to Dermatology

Intravenous Immunoglobulins: A Valuable Asset in the Treatment of a Case of Septic Febrile Ulceronecrotic Mucha-Habermann Disease

Pyrpasopoulou A.a · Athyros V.G.a · Karagiannis A.a · Chrysomallis F.b · Zamboulis C.a
a2nd Prop., Hippokration Hospital, and bDepartment of Skin Diseases, Aristotelian University, Hospital for Skin and Venereal Diseases, Thessaloniki, Greece

First-Page Preview
Abstract of Letters to Dermatology

 goto top of outline Author Contacts

Vasilios G. Athyros, MD, FASA, FACS
Department of Internal Medicine, Aristotelian University
15 Marmara Street
GR–55132 Thessaloniki (Greece)
Tel. +30 2310 454237, Fax +30 2310 445220
E-Mail athyros@med.auth.gr


 goto top of outline Article Information

Number of Print Pages : 2


 goto top of outline Publication Details

Dermatology

Vol. 215, No. 2, Year 2007 (Cover Date: August 2007)

Journal Editor: Saurat, J.-H. (Geneva)
ISSN: 1018–8665 (print), 1421–9832 (Online)

For additional information: http://www.karger.com/DRM


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.